Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer.

Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, Spencer DM, Slawin KM.

Cancer Immunol Immunother. 2017 Oct;66(10):1345-1357. doi: 10.1007/s00262-017-2027-6. Epub 2017 Jun 12.

PMID:
28608115
2.

Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ.

N Engl J Med. 2012 Dec 13;367(24):2305-15. doi: 10.1056/NEJMoa1207285.

3.

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P.

Clin Cancer Res. 2012 Dec 15;18(24):6758-70. doi: 10.1158/1078-0432.CCR-12-1177. Epub 2012 Oct 2.

4.

Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA.

PLoS One. 2012;7(4):e34833. doi: 10.1371/journal.pone.0034833. Epub 2012 Apr 25.

5.

Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.

Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJ.

Cancer Res. 2011 Jul 15;71(14):5040-9. doi: 10.1158/0008-5472.CAN-11-0842. Epub 2011 Jun 6.

6.

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.

Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG.

Clin Cancer Res. 2011 Jul 15;17(14):4882-91. doi: 10.1158/1078-0432.CCR-10-2769. Epub 2011 Jun 1.

7.

Interlaboratory assessment of a novel colony-forming unit assay: a multicenter study by the cellular team of Biomedical Excellence for Safer Transfusion (BEST) collaborative.

Nawrot M, McKenna DH, Sumstad D, McMannis JD, Szczepiorkowski ZM, Belfield H, Grassman E, Temples T, Nielsen D, Yuan N, Wognum B, Reems JA.

Transfusion. 2011 Sep;51(9):2001-5. doi: 10.1111/j.1537-2995.2011.03153.x. Epub 2011 May 13.

PMID:
21569039
8.

Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.

Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM.

J Immunother. 2010 Sep;33(7):684-96. doi: 10.1097/CJI.0b013e3181e475e9.

9.

Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.

Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C.

Leuk Lymphoma. 2010 Aug;51(8):1478-84. doi: 10.3109/10428194.2010.501534.

10.

Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.

Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT.

Int J Hematol. 2009 Dec;90(5):627-634. doi: 10.1007/s12185-009-0439-6. Epub 2009 Dec 9.

PMID:
19998065
11.

AML-loaded DC generate Th1-type cellular immune responses in vitro.

Xing D, Decker WK, Li S, Robinson SN, Yang H, Segal H, O'Connor S, Yao X, Komanduri KV, McMannis JD, Jones RB, de Lima M, Champlin RE, Shpall EJ.

Cytotherapy. 2006;8(2):95-104.

PMID:
16698683
12.

Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help.

Decker WK, Xing D, Li S, Robinson SN, Yang H, Yao X, Segall H, McMannis JD, Komanduri KV, Champlin RE, Shpall EJ.

Vaccine. 2006 Apr 12;24(16):3203-16. Epub 2006 Jan 23.

PMID:
16480795
13.

A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.

Yang H, Eaves C, de Lima M, Lee MS, Champlin RE, McMannis JD, Robinson SN, Niu T, Decker WK, Xing D, Ng J, Li S, Yao X, Eaves AC, Jones R, Andersson BS, Shpall EJ.

Bone Marrow Transplant. 2006 Mar;37(6):575-82.

PMID:
16435011
14.

Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells.

Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, Kaur I, Fu P, Del Angel M, Messinger R, Flagge F, de Lima M, Decker W, Xing D, Champlin R, Shpall EJ.

Bone Marrow Transplant. 2006 Feb;37(4):359-66.

15.

Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation.

Aviner S, Yao X, Krauthgamer R, Gan Y, Goren-Arbel R, Klein T, Tabilio A, McMannis JD, Champlin R, Martelli MF, Bachar-Lustig E, Reisner Y.

Hum Immunol. 2005 Jun;66(6):644-52.

PMID:
15993710
16.

Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.

Duzkale H, Pagliaro LC, Rosenblum MG, Varan A, Liu B, Reuben J, Wierda WG, Korbling M, McMannis JD, Glassman AB, Scheinberg DA, Freireich EJ.

Biol Blood Marrow Transplant. 2003 Jun;9(6):364-72.

17.

Role of the GMP facility for adoptive immunotherapy.

McMannis JD, Champlin RE.

Cytotherapy. 2002;4(4):329-31. No abstract available.

PMID:
12396832
18.

Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma.

Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI.

Bone Marrow Transplant. 1998 Nov;22(10):971-9.

19.

Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor.

Kawano Y, Takaue Y, Watanabe A, Takeda O, Arai K, Itoh E, Ohno Y, Teshima T, Harada M, Watanabe T, Okamoto Y, Abe T, Kajiume T, Matsushita T, Ikeda K, Endo M, Kuroda Y, Asano S, Tanosaki R, Yamaguchi K, Law P, McMannis JD.

Blood. 1998 Nov 1;92(9):3123-30.

20.

Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.

Ellis TM, Creekmore SP, McMannis JD, Braun DP, Harris JA, Fisher RI.

Cancer Res. 1988 Nov 15;48(22):6597-602.

21.
22.

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA, et al.

Cancer Res. 1988 Aug 1;48(15):4409-16.

23.

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, et al.

Ann Intern Med. 1988 Apr;108(4):518-23.

PMID:
3258138
24.

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.

McMannis JD, Fisher RI, Creekmore SP, Braun DP, Harris JE, Ellis TM.

J Immunol. 1988 Feb 15;140(4):1335-40.

PMID:
3257776
25.

Effects of anti-C4 antibody on complement production by splenic and peritoneal macrophages.

Goldman JN, O'Rourke KS, McMannis JD, Goldman MB.

Complement. 1988;5(1):13-26.

PMID:
3338270
26.

The role of lymphoid cells in antibody-induced suppression of the fourth component of guinea pig complement.

McMannis JD, Goldman MB, Goldman JN.

Cell Immunol. 1987 Apr 15;106(1):22-32.

PMID:
3494535
27.

Supplemental Content

Loading ...
Support Center